CD4 and AIDS: Among MSM, compared with ART deferral until a CD4+ less than 350 cells/μl or AIDS, a strategy of immediate ART had no impact on prevalence of HIV-serodifferent CLS (CLS-D) over the subsequent 2 years, or on related measures of frequency of such sex or partner numbers.